Hongmin Lu
1111 Xianxia Road
Shanghai, 200336, China
Shanghai, 200336, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Repurposing MDM2 inhibitor RG7388 for TP53-mutant NSCLC: a p53-independent pyroptotic mechanism via ROS/p-p38/NOXA/caspase-3/GSDME axis.
Journal: Cell death & disease
Published: February 17, 2025
A weakly supervised deep learning framework for automated PD-L1 expression analysis in lung cancer.
Journal: Frontiers in immunology
Published: December 05, 2024
Utidelone-based therapy in advanced or metastatic solid tumors after failure of standard therapies: a prospective, multicenter, single-arm trial.
Journal: American journal of cancer research
Published: March 18, 2024
Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.
Journal: Thoracic cancer
Published: November 22, 2021
The diagnostic performance of lysine(K)-specific demethylase 6B (KDM6B) in non-small cell lung cancer.
Journal: Artificial cells, nanomedicine, and biotechnology
Published: June 04, 2019
Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1*6 or UGT1A1*28.
Journal: Cancer management and research
Published: December 13, 2018
Crizotinib induces apoptosis of lung cancer cells through JAK-STAT pathway.
Journal: Oncology letters
Published: March 09, 2018
Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy.
Journal: Cancer biology & therapy
Published: March 10, 2017
Showing 1-10 of 10
Last Updated: 09/26/2026